FDA approves Novo Nordisk's Sogroya(R) as the first and only once-weekly, long-acting growth hormone for three additional pediatric indications

Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved three new indications for once-weekly Sogroya (R) (somapacitan-beco) injection 5 mg, 10 mg, or 15 mg, a ...
Healthline

Botox Side Effects: Your Guide to Safety and Long-Term Risks

This article provides an overview of Botox safety based on the latest prescribing information (PI) and clinical study data. By understanding both the possible side effects and long-term safety ...